5.37  0.47 (9.59%)		12-01 16:00
Open: 4.93 High: 5.48 Volume: 35,859		Pre. Close: 4.9 Low: 4.83 Market Cap: 128(M)

Short term
Mid term
Targets	6-month :	6.75	1-year :	7.88
Resists	First :	5.78	Second :	6.75
Pivot price	4.49
Supports	First :	4.5	Second :	3.72
MAs	MA(5) :	4.8	MA(20) :	4.56
	MA(100) :	5.59	MA(250) :	10.68
MACD	MACD :	-0.1	Signal :	-0.2
%K %D	K(14,3) :	88.7	D(3) :	75.7
RSI	RSI(14): 61.9
52-week	High :	20	Low :	3.72

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PEPG ] has closed Bollinger Bands are 25.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	5.49 - 5.51	5.51 - 5.53
Low:	4.78 - 4.8	4.8 - 4.83
Close:	5.33 - 5.37	5.37 - 5.41

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Wed, 15 Nov 2023
PepGen Announces Appointment of Howard Mayer, M.D. to Board of ... - WDRB

Wed, 08 Nov 2023
PepGen Reports Third Quarter 2023 Financial Results and Recent ... - Yahoo Finance

Thu, 19 Oct 2023
The Petri Dish: Thermo Fisher makes $3.1B buy; FDA lifts hold on ... - The Business Journals

Fri, 13 Oct 2023
Institutional investors in Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) lost 16% last week but have reaped the benefits of longer-term growth - Simply Wall St

Thu, 12 Oct 2023
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its ... - BioSpace

Fri, 01 Sep 2023
PepGen Announces Presentations at the 2023 Myotonic Dystrophy ... - BioSpace

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	24 (M)
Shares Float	8 (M)
Held by Insiders	0 (%)
Held by Institutions	97.7 (%)
Shares Short	297 (K)
Shares Short P.Month	248 (K)

EPS	-2.74
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.28
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-27.3 %
Return on Equity (ttm)	-46.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.37
Qtrly Earnings Growth	0 %
Operating Cash Flow	-63 (M)
Levered Free Cash Flow	-39 (M)

PE Ratio	-1.97
PEG Ratio	0
Price to Book value	1.01
Price to Sales	0
Price to Cash Flow	-2.04

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.